Viking Therapeutics
VKTX
138 hedge funds and large institutions have $227M invested in Viking Therapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 52 reducing their positions, and 20 closing their positions.
320% more call options, than puts
Call options by funds: $7.14M | Put options by funds: $1.7M
4% less funds holding
Funds holding: 144 → 138 (-6)
7.54% less ownership
Funds ownership: 56.03% → 48.49% (-7.5%)
13% less capital invested
Capital invested by funds: $260M → $227M (-$33.3M)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
25% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.94M |
| 2 |
Goldman Sachs
New York
|
+$1.44M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$663K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$568K |
| 5 |
PP
PDT Partners
New York
|
+$564K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.3M |
| 3 |
Two Sigma Investments
New York
|
-$1.75M |
| 4 |
Aviva
London,
United Kingdom
|
-$1.31M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.19M |
VKTX Hedge Fund Activity: Q2 2021 in Review
138 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2021, worth a combined $227M — down 13% from $260M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of VKTX and 15 opened new positions — a net loss of 5 holders — while 52 trimmed existing stakes and 39 added.
The largest buyer was Morgan Stanley, adding an estimated $1.94M. The largest seller was State Street, cutting an estimated $10.7M.
- 138 institutional investors held Viking Therapeutics (VKTX) as of Q2 2021, down from 144 in Q1 2021.
- Funds reported $227M of Viking Therapeutics stock for Q2 2021, down 13% quarter-over-quarter.
- 15 funds opened new Viking Therapeutics positions in Q2 2021 and 20 closed out, a net change of -5 holders.
- The largest Viking Therapeutics buyer in Q2 2021 was Morgan Stanley, an estimated $1.94M added.
- The largest Viking Therapeutics seller in Q2 2021 was State Street, an estimated $10.7M sold.
Based on aggregated 13F filings for Q2 2021.